二甲双胍联合格列美脲或卡格列净对老年糖尿病患者胰岛功能、血清FFA、Asprosin水平的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Metformin combined with Glimepiride or Canagliflozin on pancreatic islet function, serum free fatty acids (FFA), Asprosin levels in elderly patients with diabetes. Methods A total of 108 elderly diabetic patients admitted to the Health Management Center, the Second People′s Hospital of Foshan from June 2018 to June 2020 were selected as the research objects and divided into the control group (54 cases) and the observation group (54 cases) according to the random number table method. The control group was treated with Metformin, while the observation group was treated with Metformin combined with Glimepiride or Canagliflozin. Blood glucose (fasting plasma glucose [FPG], 2 h postprandial blood glucose [2 h PBG], glycosylated hemoglobin [HbA1c]), pancreatic islet function indicators (homeostatic model assessment of β-cell function [HOMA-β], homeostasis model assessment of insulin resistance [HOMA-IR]), serum FFA and Asprosin levels, lipid metabolism indicators(total cholesterol [TC],triglycerides [TG], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]), oxidative stress indicators (malondialdehyde [MDA], superoxide dismutase [SOD]), and the total incidence of adverse reactions were compared between the two groups. Results After treatment, the levels of FPG, 2 h PBG, HbA1c, TC, TG,LDL-C, HOMA-IR, FFA, Asprosin, MDA, and SOD of the observation group were lower than those of the control group,while the levels of HDL-β and HOMA-IR of the observation group were higher than those of the control group, the differences were statistically significant (P<0.05). There was no significant difference in the total incidences of adverse reactions between the two groups (P>0.05). Conclusion Metformin combined with Glimepiride or Canagliflozin could control blood glucose, improve pancreatic islet function and lipid metabolism, and lower serum FFA and Asprosin levels in elderly diabetic patients.

Key words： Diabetes Elderly Metformin Glimepiride;Canagliflozin Pancreatic islet function Free fatty acid;Asprosin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MAI Xue-yu
	SHEN Pei-yang
	LI Fa-biao

Cite this article:

MAI Xue-yu,SHEN Pei-yang,LI Fa-biao. Effect of Metformin combined with Glimepiride or Canagliflozin on pancreatic islet function, serum FFA, Asprosin levels in elderly patients with diabetes[J]. 中国当代医药, 2021, 28(16): 115-118.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I16/115

[1]	杨华俊，张婷婷，史东明，等.参芪降糖颗粒联合格列美脲与二甲双胍对糖尿病患者血糖水平，胰岛细胞功能及内皮因子的影响[J].中国卫生检验杂志，2019，29（22）：66-68.
[2]	刘罗坤，冯雪萍，王颖，等.津力达颗粒联合二甲双胍对老年2 型糖尿病患者血糖和血清炎性因子水平的影响[J].中国临床保健杂志，2017，20（1）：71-73.
[3]	王永海，江梅菊，王琳，等.阿托伐他汀联合二甲双胍治疗老年2 型糖尿病伴血脂异常的效果[J].中国医药导报，2018，15（13）：113-116，155.
[4]	周琼兰，张敏，孙勤，等.达格列净联合二甲双胍治疗2 型糖尿病合并阻塞性睡眠呼吸暂停综合征的疗效研究[J].实用医院临床杂志，2018，15（6）：154-157.
[5]	《中国糖尿病防治指南》编写组.中国糖尿病防治指南[M].北京：北京大学医学出版社，2004.
[6]	Liang HX.Application of comprehensive intensified management combined with metformin to diabetic patients in community[J].Chin Med，2018，31（4）：75-78.
[7]	Chen ZL，Fan X，Chen L，et al.Effect of metformin on the prognosis of diabetic patients combined with gynecologic cancer：A Meta-analysis[J].Med J Chin Peoples Liberation Army，2018，43（2）：149-157.
[8]	刘烈华，许丽娟，柯伟健，等.短程胰岛素强化治疗后二甲双胍联合吡格列酮序贯治疗对新诊断2 型糖尿病患者的作用[J].中华糖尿病杂志，2020，12（9）：696-701.
[9]	李锦伟.格列美脲联合二甲双胍治疗2 型糖尿病的疗效及血糖水平分析[J].中国急救医学，2018，38（2）：84.
[10]	李莉.沙格列汀和格列美脲对二甲双胍不耐受2 型糖尿病患者的疗效比较[J].微循环学杂志，2017，27（2）：62-66.
[11]	张童，鲁佳，叶山东，等.利拉鲁肽联合格列美脲和二甲双胍治疗难治性2 型糖尿病的临床疗效及对胰岛功能的影响分析[J].世界临床药物，2020，34（4）：65-69.
[12]	宁红，饶友义，谢佳峻，等.SGLT-2 抑制剂与其他降糖药物对比治疗2 型糖尿病有效性与安全性的网状Meta 分析[J].中国医院药学杂志，2019，39（24）：2529-2536.
[13]	谈晓娅，童强.格列美脲联合二甲双胍对初诊2 型糖尿病患者糖脂代谢、胰岛功能及血清miR-126 表达的影响[J].中国药房，2018，29（4）：505-508.
[14]	刘师伟，吴亚茹，段瑞雪，等.2 型糖尿病患者血清Asprosin 水平及其与代谢指标的相关性研究[J].重庆医科大学学报，2018，43（12）：83-88.
[15]	章丹，曾婷婷，徐海燕，等.达格列净联合二甲双胍治疗2 型糖尿病疗效观察[J].药物流行病学杂志，2018，27（10）：637-639.
[16]	刘慧莹，程刚.西格列汀，格列美脲分别联合二甲双胍治疗2 型糖尿病有效性与安全性Meta 分析[J].临床军医杂志，2020，48（2）：71-74.
[17]	张童，鲁佳，叶山东，等.利拉鲁肽联合格列美脲和二甲双胍治疗难治性2 型糖尿病的临床疗效及对胰岛功能的影响分析[J].世界临床药物，2020，34（4）：65-69.
[18]	陈春燕、张时清、张浩，等.达格列净联合二甲双胍对糖尿病患者的临床疗效及相关内分泌激素水平的影响[J].中国临床医生杂志，2020，48（9）：43-45.
[19]	汪洋，汪建龙，周盛，等.格列美脲联合二甲双胍治疗对新诊断T2MD 患者控糖效果及副作用的长期随访观察[J].解放军预防医学杂志，2019，37（3）：124-125.
[20]	周莉桢，郭杏花，郑仲萍，等.二甲双胍联合降糖药物对2型糖尿病病人血糖控制率、血糖相关指标及胰岛β 细胞功能指标的影响[J].中西医结合心脑血管病杂志，2019，17（8）：1233-1235.